-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Purpose :
Purpose Purpose :There are still no disease-modifying antirheumatic drugs approved for patients with primary Sjögren's syndrome (pSS) toda.
There are still no disease-modifying antirheumatic drugs approved for patients with primary Sjögren's syndrome (pSS) toda.
Method :
methodTo develop STAR , the NECESSITY (New Clinical Endpoint in Primary Sjögren's Syndrome: Interventional Trial Based on Patient Stratification) consortium used a data-driven approach based on nine randomised controlled trials (RCTs) and involving 78 specialists and 20 patients consensus technolo.
To develop STAR , the NECESSITY (New Clinical Endpoint in Primary Sjögren's Syndrome: Interventional Trial Based on Patient Stratification) consortium used a data-driven approach based on nine randomised controlled trials (RCTs) and involving 78 specialists and 20 patients consensus technolo.
STAR options combining these areas were presented to the panel for selection and improveme.
result
The Delphi team identified five core domains (systemic activity, patient symptoms, lacrimal gland function, salivary gland function, and biological parameters) and selected 227 STAR options combining these domains to test for sensitivity to change.
The Delphi team identified five core domains (systemic activity, patient symptoms, lacrimal gland function, salivary gland function, and biological parameters) and selected 227 STAR options combining these domains to test for sensitivity to change.
in conclusion
Candidate STAR is a composite response index that includes all major disease characteristics in one tool and is intended to be used as the primary endpoint in pSS RCT.
Candidate STAR is a composite response index that includes all major disease characteristics in one tool and is intended to be used as the primary endpoint in pSS RCT.
Source:
Seror R, Baron G, Camus M on behalf of the NECESSITY WP5 - STAR development working group , et a.
Seror R, Baron G, Camus M on behalf of the NECESSITY WP5 - STAR development working group , et a.
Development and preliminary validation of the Sjögren's Tool for Assessing Response (STAR): a consensual composite score for assessing treatment effect in primary Sjögren's syndrom.
Annals of the Rheumatic Diseases2022;81 : 979-98 , et al Annals of the Rheumatic Diseases: Leave a comment here
